Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11313174rdf:typepubmed:Citationlld:pubmed
pubmed-article:11313174lifeskim:mentionsumls-concept:C0007082lld:lifeskim
pubmed-article:11313174lifeskim:mentionsumls-concept:C0032790lld:lifeskim
pubmed-article:11313174lifeskim:mentionsumls-concept:C1527249lld:lifeskim
pubmed-article:11313174lifeskim:mentionsumls-concept:C0733511lld:lifeskim
pubmed-article:11313174lifeskim:mentionsumls-concept:C0032743lld:lifeskim
pubmed-article:11313174pubmed:issue7lld:pubmed
pubmed-article:11313174pubmed:dateCreated2001-4-23lld:pubmed
pubmed-article:11313174pubmed:abstractTextThe aim of the study was to evaluate the use of positron emission tomography with [18F]-fluorodeoxyglucose (FDG-PET) in patients with unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer. 50 consecutive patients with elevated CEA levels and a completely normal (n=31) or equivocal (n=19) conventional diagnostic work-up (CDW) were retrospectively selected. All PET images were reviewed with full knowledge of the CDW. The gold standard consisted of histology, or clinical follow-up of more than 1 year. Recurrent disease was established in 56 lesions in 43 patients. On a patient-based analysis, the sensitivity of FDG-PET was 34/43 (79%), and the positive predictive value 34/38 (89%). In 14/50 patients (28%), the FDG-PET findings led to a surgical resection with curative intent. On a lesion-based analysis, FDG-PET detected 42/56 lesions (sensitivity: 75%), the positive predictive value was 79% (42/53). These results demonstrate that FDG-PET can have a clear impact on patient management in patients with an unexplained elevation in CEA levels.lld:pubmed
pubmed-article:11313174pubmed:languageenglld:pubmed
pubmed-article:11313174pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11313174pubmed:citationSubsetIMlld:pubmed
pubmed-article:11313174pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11313174pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11313174pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11313174pubmed:statusMEDLINElld:pubmed
pubmed-article:11313174pubmed:monthMaylld:pubmed
pubmed-article:11313174pubmed:issn0959-8049lld:pubmed
pubmed-article:11313174pubmed:authorpubmed-author:FilerDDlld:pubmed
pubmed-article:11313174pubmed:authorpubmed-author:PeetersMMlld:pubmed
pubmed-article:11313174pubmed:authorpubmed-author:PenninckxFFlld:pubmed
pubmed-article:11313174pubmed:authorpubmed-author:MortelmansLLlld:pubmed
pubmed-article:11313174pubmed:authorpubmed-author:HoekstraO SOSlld:pubmed
pubmed-article:11313174pubmed:authorpubmed-author:Van CutsemEElld:pubmed
pubmed-article:11313174pubmed:authorpubmed-author:MaesAAlld:pubmed
pubmed-article:11313174pubmed:authorpubmed-author:BleichrodtR...lld:pubmed
pubmed-article:11313174pubmed:authorpubmed-author:FlamenPPlld:pubmed
pubmed-article:11313174pubmed:authorpubmed-author:StroobantsSSlld:pubmed
pubmed-article:11313174pubmed:authorpubmed-author:HomansFFlld:pubmed
pubmed-article:11313174pubmed:issnTypePrintlld:pubmed
pubmed-article:11313174pubmed:volume37lld:pubmed
pubmed-article:11313174pubmed:ownerNLMlld:pubmed
pubmed-article:11313174pubmed:authorsCompleteYlld:pubmed
pubmed-article:11313174pubmed:pagination862-9lld:pubmed
pubmed-article:11313174pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:meshHeadingpubmed-meshheading:11313174...lld:pubmed
pubmed-article:11313174pubmed:year2001lld:pubmed
pubmed-article:11313174pubmed:articleTitleUnexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET).lld:pubmed
pubmed-article:11313174pubmed:affiliationDepartments of Nuclear Medicine, Internal Medicine, and Abdominal Surgery, University Hospital Gasthuisberg, Katholieke Universiteit Leuven (KUL), Herestraat 49, 3000, Leuven, Belgium. patrick.flamen@uz.kuleuven.ac.belld:pubmed
pubmed-article:11313174pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11313174lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11313174lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11313174lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11313174lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11313174lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11313174lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11313174lld:pubmed